nodes	percent_of_prediction	percent_of_DWPC	metapath
Metyrapone—ABCC3—Methotrexate—systemic scleroderma	0.291	0.715	CbGbCtD
Metyrapone—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0644	0.158	CbGbCtD
Metyrapone—CYP3A4—Prednisone—systemic scleroderma	0.0515	0.127	CbGbCtD
Metyrapone—Adrenal insufficiency—Prednisone—systemic scleroderma	0.0256	0.0432	CcSEcCtD
Metyrapone—Endocrine disorder—Mometasone—systemic scleroderma	0.0175	0.0295	CcSEcCtD
Metyrapone—Hirsutism—Mycophenolic acid—systemic scleroderma	0.0173	0.0291	CcSEcCtD
Metyrapone—Bone marrow depression—Azathioprine—systemic scleroderma	0.0165	0.0278	CcSEcCtD
Metyrapone—Hirsutism—Mycophenolate mofetil—systemic scleroderma	0.0136	0.023	CcSEcCtD
Metyrapone—Bone marrow depression—Lisinopril—systemic scleroderma	0.0134	0.0226	CcSEcCtD
Metyrapone—Endocrine disorder—Leflunomide—systemic scleroderma	0.0127	0.0214	CcSEcCtD
Metyrapone—Endocrine disorder—Mycophenolic acid—systemic scleroderma	0.0121	0.0204	CcSEcCtD
Metyrapone—Bone marrow depression—Mycophenolate mofetil—systemic scleroderma	0.0117	0.0198	CcSEcCtD
Metyrapone—Endocrine disorder—Lisinopril—systemic scleroderma	0.0109	0.0184	CcSEcCtD
Metyrapone—Abdominal discomfort—Pentoxifylline—systemic scleroderma	0.0101	0.0171	CcSEcCtD
Metyrapone—Pancytopenia—Pentoxifylline—systemic scleroderma	0.01	0.0169	CcSEcCtD
Metyrapone—Hirsutism—Prednisone—systemic scleroderma	0.00923	0.0156	CcSEcCtD
Metyrapone—Pancytopenia—Captopril—systemic scleroderma	0.0076	0.0128	CcSEcCtD
Metyrapone—Dermatitis atopic—Prednisone—systemic scleroderma	0.00725	0.0122	CcSEcCtD
Metyrapone—Abdominal discomfort—Azathioprine—systemic scleroderma	0.0067	0.0113	CcSEcCtD
Metyrapone—Bone marrow depression—Methotrexate—systemic scleroderma	0.00664	0.0112	CcSEcCtD
Metyrapone—Pancytopenia—Azathioprine—systemic scleroderma	0.00663	0.0112	CcSEcCtD
Metyrapone—Endocrine disorder—Prednisone—systemic scleroderma	0.00647	0.0109	CcSEcCtD
Metyrapone—Hypertension—Pentoxifylline—systemic scleroderma	0.00635	0.0107	CcSEcCtD
Metyrapone—Pancytopenia—Leflunomide—systemic scleroderma	0.00627	0.0106	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.00622	0.0105	CcSEcCtD
Metyrapone—Pancytopenia—Mycophenolic acid—systemic scleroderma	0.00598	0.0101	CcSEcCtD
Metyrapone—Skin disorder—Pentoxifylline—systemic scleroderma	0.00583	0.00983	CcSEcCtD
Metyrapone—Alopecia—Captopril—systemic scleroderma	0.00566	0.00954	CcSEcCtD
Metyrapone—Hypotension—Pentoxifylline—systemic scleroderma	0.00561	0.00946	CcSEcCtD
Metyrapone—Pancytopenia—Lisinopril—systemic scleroderma	0.00538	0.00907	CcSEcCtD
Metyrapone—Alopecia—Azathioprine—systemic scleroderma	0.00494	0.00833	CcSEcCtD
Metyrapone—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.00491	0.00828	CcSEcCtD
Metyrapone—Abdominal pain—Pentoxifylline—systemic scleroderma	0.00475	0.008	CcSEcCtD
Metyrapone—Pancytopenia—Mycophenolate mofetil—systemic scleroderma	0.00472	0.00795	CcSEcCtD
Metyrapone—Alopecia—Leflunomide—systemic scleroderma	0.00467	0.00786	CcSEcCtD
Metyrapone—Angiopathy—Mycophenolic acid—systemic scleroderma	0.00457	0.0077	CcSEcCtD
Metyrapone—Alopecia—Mycophenolic acid—systemic scleroderma	0.00445	0.0075	CcSEcCtD
Metyrapone—Pain—Mometasone—systemic scleroderma	0.00443	0.00747	CcSEcCtD
Metyrapone—Hypotension—Captopril—systemic scleroderma	0.00425	0.00717	CcSEcCtD
Metyrapone—Gastrointestinal pain—Mometasone—systemic scleroderma	0.00424	0.00714	CcSEcCtD
Metyrapone—Angiopathy—Lisinopril—systemic scleroderma	0.00412	0.00694	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00412	0.00694	CcSEcCtD
Metyrapone—Abdominal pain—Mometasone—systemic scleroderma	0.0041	0.0069	CcSEcCtD
Metyrapone—Alopecia—Lisinopril—systemic scleroderma	0.00401	0.00676	CcSEcCtD
Metyrapone—Dizziness—Pentoxifylline—systemic scleroderma	0.00397	0.00669	CcSEcCtD
Metyrapone—Hypertension—Leflunomide—systemic scleroderma	0.00397	0.00669	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00389	0.00655	CcSEcCtD
Metyrapone—Skin disorder—Azathioprine—systemic scleroderma	0.00386	0.0065	CcSEcCtD
Metyrapone—Vomiting—Pentoxifylline—systemic scleroderma	0.00382	0.00644	CcSEcCtD
Metyrapone—Hypertension—Mycophenolic acid—systemic scleroderma	0.00379	0.00638	CcSEcCtD
Metyrapone—Headache—Pentoxifylline—systemic scleroderma	0.00376	0.00634	CcSEcCtD
Metyrapone—Gastrointestinal pain—Captopril—systemic scleroderma	0.00372	0.00627	CcSEcCtD
Metyrapone—Hypotension—Azathioprine—systemic scleroderma	0.00371	0.00626	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00371	0.00625	CcSEcCtD
Metyrapone—Nervous system disorder—Leflunomide—systemic scleroderma	0.00368	0.0062	CcSEcCtD
Metyrapone—Skin disorder—Leflunomide—systemic scleroderma	0.00364	0.00614	CcSEcCtD
Metyrapone—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00361	0.00608	CcSEcCtD
Metyrapone—Abdominal pain—Captopril—systemic scleroderma	0.0036	0.00606	CcSEcCtD
Metyrapone—Nausea—Pentoxifylline—systemic scleroderma	0.00357	0.00601	CcSEcCtD
Metyrapone—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.00351	0.00592	CcSEcCtD
Metyrapone—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00351	0.00592	CcSEcCtD
Metyrapone—Hypotension—Leflunomide—systemic scleroderma	0.00351	0.00591	CcSEcCtD
Metyrapone—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00348	0.00586	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00343	0.00578	CcSEcCtD
Metyrapone—Hypotension—Mycophenolic acid—systemic scleroderma	0.00334	0.00564	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00334	0.00563	CcSEcCtD
Metyrapone—Vomiting—Mometasone—systemic scleroderma	0.0033	0.00555	CcSEcCtD
Metyrapone—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00325	0.00547	CcSEcCtD
Metyrapone—Headache—Mometasone—systemic scleroderma	0.00325	0.00547	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00324	0.00546	CcSEcCtD
Metyrapone—Pain—Leflunomide—systemic scleroderma	0.00321	0.00541	CcSEcCtD
Metyrapone—Abdominal pain—Azathioprine—systemic scleroderma	0.00314	0.00529	CcSEcCtD
Metyrapone—Skin disorder—Lisinopril—systemic scleroderma	0.00313	0.00528	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00309	0.00521	CcSEcCtD
Metyrapone—Nausea—Mometasone—systemic scleroderma	0.00308	0.00519	CcSEcCtD
Metyrapone—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00307	0.00517	CcSEcCtD
Metyrapone—Pain—Mycophenolic acid—systemic scleroderma	0.00306	0.00516	CcSEcCtD
Metyrapone—Hypotension—Lisinopril—systemic scleroderma	0.00301	0.00508	CcSEcCtD
Metyrapone—Dizziness—Captopril—systemic scleroderma	0.00301	0.00507	CcSEcCtD
Metyrapone—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00299	0.00504	CcSEcCtD
Metyrapone—Abdominal pain—Leflunomide—systemic scleroderma	0.00297	0.005	CcSEcCtD
Metyrapone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00293	0.00493	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00293	0.00493	CcSEcCtD
Metyrapone—Vomiting—Captopril—systemic scleroderma	0.00289	0.00488	CcSEcCtD
Metyrapone—Headache—Captopril—systemic scleroderma	0.00285	0.00481	CcSEcCtD
Metyrapone—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00283	0.00477	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00278	0.00469	CcSEcCtD
Metyrapone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00277	0.00467	CcSEcCtD
Metyrapone—Pain—Lisinopril—systemic scleroderma	0.00276	0.00465	CcSEcCtD
Metyrapone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00274	0.00462	CcSEcCtD
Metyrapone—Nausea—Captopril—systemic scleroderma	0.0027	0.00456	CcSEcCtD
Metyrapone—Abdominal discomfort—Methotrexate—systemic scleroderma	0.0027	0.00455	CcSEcCtD
Metyrapone—Pancytopenia—Methotrexate—systemic scleroderma	0.00267	0.0045	CcSEcCtD
Metyrapone—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00264	0.00445	CcSEcCtD
Metyrapone—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00264	0.00444	CcSEcCtD
Metyrapone—Dizziness—Azathioprine—systemic scleroderma	0.00263	0.00443	CcSEcCtD
Metyrapone—Abdominal pain—Lisinopril—systemic scleroderma	0.00255	0.00429	CcSEcCtD
Metyrapone—Vomiting—Azathioprine—systemic scleroderma	0.00253	0.00426	CcSEcCtD
Metyrapone—Headache—Azathioprine—systemic scleroderma	0.00249	0.00419	CcSEcCtD
Metyrapone—Dizziness—Leflunomide—systemic scleroderma	0.00248	0.00418	CcSEcCtD
Metyrapone—Angiopathy—Prednisone—systemic scleroderma	0.00245	0.00412	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00244	0.00411	CcSEcCtD
Metyrapone—Pain—Mycophenolate mofetil—systemic scleroderma	0.00242	0.00407	CcSEcCtD
Metyrapone—Vomiting—Leflunomide—systemic scleroderma	0.00239	0.00402	CcSEcCtD
Metyrapone—Alopecia—Prednisone—systemic scleroderma	0.00238	0.00401	CcSEcCtD
Metyrapone—Dizziness—Mycophenolic acid—systemic scleroderma	0.00237	0.00399	CcSEcCtD
Metyrapone—Nausea—Azathioprine—systemic scleroderma	0.00236	0.00398	CcSEcCtD
Metyrapone—Headache—Leflunomide—systemic scleroderma	0.00235	0.00396	CcSEcCtD
Metyrapone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00231	0.00389	CcSEcCtD
Metyrapone—Vomiting—Mycophenolic acid—systemic scleroderma	0.00228	0.00384	CcSEcCtD
Metyrapone—Headache—Mycophenolic acid—systemic scleroderma	0.00224	0.00378	CcSEcCtD
Metyrapone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00223	0.00376	CcSEcCtD
Metyrapone—Nausea—Leflunomide—systemic scleroderma	0.00223	0.00376	CcSEcCtD
Metyrapone—Dizziness—Lisinopril—systemic scleroderma	0.00213	0.00359	CcSEcCtD
Metyrapone—Nausea—Mycophenolic acid—systemic scleroderma	0.00213	0.00358	CcSEcCtD
Metyrapone—Vomiting—Lisinopril—systemic scleroderma	0.00205	0.00345	CcSEcCtD
Metyrapone—Angiopathy—Methotrexate—systemic scleroderma	0.00204	0.00344	CcSEcCtD
Metyrapone—Hypertension—Prednisone—systemic scleroderma	0.00203	0.00341	CcSEcCtD
Metyrapone—Headache—Lisinopril—systemic scleroderma	0.00202	0.0034	CcSEcCtD
Metyrapone—Alopecia—Methotrexate—systemic scleroderma	0.00199	0.00335	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00198	0.00334	CcSEcCtD
Metyrapone—Nausea—Lisinopril—systemic scleroderma	0.00191	0.00323	CcSEcCtD
Metyrapone—Nervous system disorder—Prednisone—systemic scleroderma	0.00188	0.00316	CcSEcCtD
Metyrapone—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00187	0.00315	CcSEcCtD
Metyrapone—Skin disorder—Prednisone—systemic scleroderma	0.00186	0.00313	CcSEcCtD
Metyrapone—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.0018	0.00303	CcSEcCtD
Metyrapone—Headache—Mycophenolate mofetil—systemic scleroderma	0.00177	0.00298	CcSEcCtD
Metyrapone—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00168	0.00283	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.00166	0.00279	CcSEcCtD
Metyrapone—Nervous system disorder—Methotrexate—systemic scleroderma	0.00157	0.00264	CcSEcCtD
Metyrapone—Gastrointestinal pain—Prednisone—systemic scleroderma	0.00157	0.00264	CcSEcCtD
Metyrapone—Skin disorder—Methotrexate—systemic scleroderma	0.00155	0.00262	CcSEcCtD
Metyrapone—Abdominal pain—Prednisone—systemic scleroderma	0.00151	0.00255	CcSEcCtD
Metyrapone—Hypotension—Methotrexate—systemic scleroderma	0.0015	0.00252	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.00138	0.00233	CcSEcCtD
Metyrapone—Pain—Methotrexate—systemic scleroderma	0.00137	0.00231	CcSEcCtD
Metyrapone—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.00131	0.00221	CcSEcCtD
Metyrapone—Dizziness—Prednisone—systemic scleroderma	0.00127	0.00213	CcSEcCtD
Metyrapone—Abdominal pain—Methotrexate—systemic scleroderma	0.00126	0.00213	CcSEcCtD
Metyrapone—Vomiting—Prednisone—systemic scleroderma	0.00122	0.00205	CcSEcCtD
Metyrapone—Headache—Prednisone—systemic scleroderma	0.0012	0.00202	CcSEcCtD
Metyrapone—Nausea—Prednisone—systemic scleroderma	0.00114	0.00192	CcSEcCtD
Metyrapone—Dizziness—Methotrexate—systemic scleroderma	0.00106	0.00178	CcSEcCtD
Metyrapone—Vomiting—Methotrexate—systemic scleroderma	0.00102	0.00171	CcSEcCtD
Metyrapone—Headache—Methotrexate—systemic scleroderma	0.001	0.00169	CcSEcCtD
Metyrapone—Nausea—Methotrexate—systemic scleroderma	0.00095	0.0016	CcSEcCtD
